India Globalization Capital, Inc. (NYSE: IGC) Positioned to Lead in Phytocannabinoid Pharmaceuticals

A study recently highlighted by the American Epilepsy Society (AES) at its 70th annual meeting focused on the potential of cannabidiol (CBD), a derivative of the cannabis plant, as a promising treatment for reducing both the frequency and severity of seizures in children with drug resistant epilepsies ( According to the study, patients who received CBD treatment exhibited over 45 percent mean reduction in seizures, and researchers were outspoken in support of further research.

Cannabidiol is the most abundant non-psychoactive cannabinoid found in the cannabis plant. Both anecdotal evidence and pre-clinical research have suggested that CBD may have a broad range of beneficial therapeutic uses in humans and animals including pain mitigation, epileptic seizures and wasting disease eating disorders (cachexia). Animal studies have also shown promise for CBD’s anticonvulsant efficacy in multiple species (

As referenced in a recent article (, multiple companies compete in the $65 billion diverse pet product market, with about $15 billion spent on veterinary care annually in the United States. Seizures afflict about five percent of the 90 million dogs in the U.S. and a little over two percent of the 94 million felines. The most commonly used drugs to treat pet seizures include a lifetime regimen of phenobarbital, potassium bromide, and diazepam. India Globalization Capital, Inc. (NYSE MKT: IGC) is changing the paradigm of seizure treatments for dogs and cats based on its novel patent pending therapy using cannabinoid extracts.

India Globalization Capital is actually building a broad portfolio of multiple intellectual properties around the utilization of phytocannabinoid-based therapies in both animals and humans. The company is at the forefront of the combined use of cannabis-based extracts with other medications to reduce side effects and to increase bioavailability and absorption (phytocannabinoid-based combination therapy).

IGC has developed a pipeline of patent pending cannabinoid-based drugs targeting large market disorders such as therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy and eating disorders. Several of these therapeutic compounds are scheduled for pre-clinical trials this year. With a team of experts encompassing patent law, clinical trials and regulatory procedures, IGC is positioned to become a leader in specialty pharmaceuticals and offers an interesting opportunity to profit from this exciting new market.

For more information, visit the company’s website at

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s